Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 165   

Articles published

BMY 71.96 -0.22 (-0.30%)
price chart
Bristol-Myers Squibb realtor is promoting facility internationally
A file photo of Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway. Photo courtesy of Bristol-Myers Squibb . It came from a site fact sheet provided to us from the company in 1994.
Burt Wealth Advisors buys $482090 stake in Bristol-Myers Squibb Co (BMY)  Market Digest
Two Biotech stocks to Watch: Bristol-Myers Squibb Company (NYSE:BMY ...  Is stories
Bristol-Myers Squibb Co. | $BMY Stock | Shares Gap Up On Solid First Quarter ...
Before the market opened on Thursday, Bristol-Myers Squibb (BMY) announced first quarter earnings that topped analyst expectations and sent shares gapping up.
Earnings Whispers: AbbVie Inc (ABBV), Bristol-Myers Squibb Co (BMY), Celgene ...  Daily Caller
BRISTOL-MYERS SQUIBB CO (BMY) Earnings Report: Q1 2016 Conference Call ...  TheStreet.com
Stock's Overbuying Recap: Bristol-Myers Squibb Co (NYSE:BMY)
Bristol-Myers Squibb Co (NYSE:BMY) has an ABR 2.37 which is the combined stock view of 15 analysts poll results. As per the Zacks simplified descending rating scale, the ABR rank is displayed in the range of 1 to 5 where 1 represents a Strong Buy and 5 ...
Stock Grabbing Investor's Attention: Bristol-Myers Squibb Company (BMY)
Bristol-Myers Squibb Company (BMY) shares closed at price of $72.18 by scoring -0.11% during its last trade. The shares of this company currently has mean rating of Outperform while 7 analysts have recommended the shares as BUY, 6 recommended as ...
Bristol-Myers Squibb Company (BMY) Falls Further As It's Water-Logged And ...
Trade-Ideas LLC identified Bristol-Myers Squibb Company ( BMY) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate.
Bristol-Myers Squibb Co Q1 Earnings: Here's What to Expect  Bidness ETC
Bristol-Myers Squibb to Take Part in Deutsche Bank Annual Health Care Conference  Business Wire (press release)
Overbuying Stock in the Spotlight: Bristol-Myers Squibb Co (NYSE:BMY)
Bristol-Myers Squibb Co (NYSE:BMY) has an ABR 2.37 which is the combined stock view of 15 analysts poll results. As per the Zacks simplified descending rating scale, the ABR rank is displayed in the range of 1 to 5 where 1 represents a Strong Buy and 5 ...
Bristol-Myers Squibb Co (BMY): How it Took an Unbeatable Lead in Immuno ...
Bristol-Myers Squibb Co (NYSE:BMY) presented clinical data at the annual meeting of American Association for Cancer Research (AACR) mentioning that Opdivo (nivolumab) can enhance the survival rate in patients suffering from recurrent or metastatic ...
Stock to Buy: Many Are Considering Bristol-Myers Squibb Co (NYSE:BMY)  The Point Review
Bristol-Myers Squibb Company (NYSE:BMY) topped earnings-per-share estimates ...  Zergwatch
Accounts Payable Update From Bristol-Myers Squibb Company (NYSE:BMY)
Bristol-Myers Squibb Company (NYSE:BMY) posted accounts payable of $1565 millions for the fiscal ended 2015-12-31. For the quarter ended 2015-12-31 accounts payable was $1565 millions.
Bristol-Myers Squibb Company (NYSE:BMY) Analyst Recommendation Outlook
Covering analysts usually give Buy, Sell and Hold recommendations along with guidance and company earnings projections. There are currently 14 analysts providing ratings for Bristol-Myers Squibb Company (NYSE:BMY). 7 have rated the stock a “Strong ...
Can Bristol-Myers Squibb Co Opdivo Lead the Immuno-Oncology Market?
Bristol-Myers Squibb Co. (NYSE:BMY) announced that its immunotherapy drug, Opdivo (nivolumab), has been granted a priority review by Food and Drug Administration (FDA) for the treatment of classical Hodgkin lymphoma.
Drug giant plots Peninsula expansion, 150 more jobs  San Francisco Business Times (blog)
Bristol-Myers Squibb to Support AmeriCares and the Clinton Health Access ...  Business Wire (press release)